Skip Navigation
Skip to contents

IUMS 2020

View GNB

IUMS Daejeon 2020

COVID-19 Special Symposium
(Co-Organized by Daejeon Metropolitan City & Ministry of Health and Welfare)

The recent pandemic of COVID-19 (coronavirus disease 2019), which caused by the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) started in Wuhan, China at the end of 2019, has recorded more than 30 million cases of infection and over 1 million deaths worldwide to date. Although such conditions are almost a year old, the accessibility of effective vaccines and therapeutics against the COVID-19 virus or disease is still far from the world. Under these circumstances, the global scientific community has made a great deal of dedication and effort to provide insight into COVID-19 knowledge from the very beginning of the pandemic outbreak to the present. Nevertheless, there are also knowledge gaps that are still unknown or need to be clarified. Therefore, in order to broaden the understanding of COVID-19 response, which has already entered the long-term epidemic, the IUMS 2020 and Daejeon Metropolitan City organized three COVID-19 special sessions as follows.

Special Lecture

Special Lecture
[SL1] Transcriptome and Proteome of SARS-CoV-2
V. Narry Kim (Seoul National University, Republic of Korea)

COVID-19 Special Sessions

COVID-19 Special Sessions
[SS1] Viral ecology and characteristics of SARS-CoV-2
When an unknown viral pathogen such as SARS-CoV-2 which causing COVID-19, introduces to human being with public health threatening, the most important activity is understanding of the pathogenicity of the virus itself. These include host responses such as analyzing the immune status of the before and/or after infection of the pathogen. Scientific knowledge and experience with a new pathogen infection have never been explored when the virus identified. Accordingly, lessons from similar diseases that have been experienced are of useful to help understanding bran-new pathogen. In this session, the latest scientific knowledge will be discussed on the basic properties of these viruses and the characteristics of their host response to infection.
Bart L. Haagmans (Erasmus University Medical Centre, Netherlands)
[SS1-2] Identification of Genes Differentially Expressed in Response to SARS-CoV-2 Infection in the Non-human Primate Model for COVID-19
Eun-Young Kim (Northwestern University, USA)
[SS2] Medical interventions using vaccine and therapeutics
To respond to a disaster that has not been experienced, non-medical interventions such as social distancing and wearing masks have been making great contributions to defending against the COVID-19 so far. More importantly, ultimate disease control requires medical accessibility of appropriate therapeutics and preventive vaccines to establish host defense equipment through securing immunity. In this session, the latest scientific knowledge will be discussed on the basic properties of these viruses and the characteristics of their host response to infection. In this session, a review and scientific advances of the antiviral development accomplished by the drug-repurposing strategy and the cutting-edge platforms for vaccine development technology will be discussed.
[SS2-1] Current status of therapeutic and virological study of SARS-CoV-2
Jeong-Sun Yang (National Institute of Health, Korea)
[SS2-2] An inhaled corticosteroid ciclesonide is a potent blocker of SARS-CoV-2 replication
Shutoku Matsuyama (National Institute of Infectious Diseases, Japan)
[SS2-3] Spontaneous Particulate Presentation Enhances Immunogenicity of the SARS-CoV-2 RBD
Jonathan F. Lovell (University at Buffalo, USA)
[SS3] Diagnosis and response for the control of COVID-19
Securing fast and accurate identification of causative pathogen in order to provide scientific clues and direction in response of SARS-CoV-2 infection is the prerequisite factor for early response of the pandemic. After the identification strategy has been stable, various ways of public health response strategies have been implemented to prevent further transmission and spreading of the disease based on pathogen diagnosis and chasing. In this session, scientific bases of molecular diagnostics that played a major role in the pathogen recognition process and future direction of molecular diagnostic strategy will be discussed. In addition, successful plans and policies executed by public health authority will be pointed out in detail.
[SS3-1] Mass Screening in the COVID-19 Pandemic
Nackmoon Sung (Clinical Research Institute, Seegene Medical Foundation, Republic of Korea)
[SS3-2] Virologic characteristics of cases of COVID-19 in Northern Vietnam, January to May, 2020
Le Thi Quynh Mai (National Institute of Hygiene and Epidemiology, Vietnam)
[SS3-3] Strategy and response against COVID-19 in Korea
Jin Gwack (Korea Disease Control and Prevention Agency, Republic of Korea)

Forums for Companies

Forums for Companies (For Korean Only)
Daejeon Metropolitan City Bio Enterprise Growth Forums
[Forum 1] Strategy for Globalization of Diagnotics Companies in Daejeon
대전지역 코로나19 대응 진단기업의 글로벌 성장전략
Participating Companies (참여기업)
Bioneer, Inc. (Han O Park, CEO) / 바이오니아(박한오 대표)
Sugentech, Inc. (Mi Jin Son, CEO) / 수젠텍(손미진 대표)
Solgent,Co.,Ltd (Jae-Hyung You, CEO) / ㈜솔젠트 (유재형 대표)
RevoSketch, Inc. (Sungwoon Lee, CEO) / ㈜레보스케치 (이성운 대표)
[Forum 2] Global Development Trends of Anti—Cancer Immune Cell Therapy/Antibody Therapy and Company Support Strategy through Open Innovation
면역항암치료제/항체치료제 글로벌 개발 동향 및 오픈 이노베이션을 통한 기업 지원 전략
Participating Companies (참여기업)
Curocell (Gunsoo Kim, Founder & CEO) / 큐로셀(김건수 대표)
PharmAbcine (Jin San Yoo, Founder & CEO) / 파맵신(유진산 대표)
YBIOLOGICS (Young Woo Park, - Founder & CEO) / 와이바이오로직스(박영우 대표)
Orum Therapeutics (SJ Lee, Founder & CEO) / 오름테라퓨틱(이승주 대표)

Public Lecture

Public Lecture (For Korean Only)
The past, present and future of COVID-19 based on the nature of virus and the history of the virus epidemic
바이러스의 속성과 전염병 역사를 통해 알아보는 코로나19의 과거와 현재, 그리고 미래
Yong Seok Jeong/정용석 (Kyung Hee University)/(경희대학교)

Go Top

Organized by
National Organizing Committee
Chairman: Sang-Ki Rhee
Address: 27, Daehak-ro, Yuseong-gu, Daejeon 34168, Korea
Business License No.: 732-80-00415
Secretariat of IUMS 2020 Daejeon, Korea
P.O.D Communications, Inc.
#10F, W-building, SKV1 Center, 11, Dangsan-ro 41-gil,
Yongdeungpo-gu, Seoul 07217, Korea
Tel: +82-70-4711-3211
Fax: +82-2-325-1720
Scientific Program Email:
Registration Email:

  • instargram
  • facebook
  • youtube